Featured Research

from universities, journals, and other organizations

Cholera vaccination beneficial, post-outbreak

Date:
January 25, 2011
Source:
Public Library of Science
Summary:
Researchers newly report evidence that vaccination against cholera can be beneficial even after an outbreak has begun.

Researchers newly report evidence that vaccination against cholera can be beneficial even after an outbreak has begun. Rita Reyburn, Dr. Lorenz von Seidlein, Dr. John Clemens and colleagues at the International Vaccine Institute (IVI) in Seoul, Korea analyze the impact that vaccination could have had on recent outbreaks around the globe in "The case for reactive mass oral cholera vaccinations," and Drs. Dang Duc Anh and Anna Lena Lopez and colleagues at IVI and in Vietnam report on the impact of such "reactive" use of vaccine during an outbreak in "Use of oral cholera vaccines in an outbreak in Vietnam: a case control study."

Both studies found a benefit to vaccination, and an accompanying editorial by Dr. Edward T. Ryan of Massachusetts General Hospital and Harvard University, "The Cholera Pandemic, Still with Us after Half a Century: Time to Rethink," comments on the significance of the works, especially in light of recent events in Haiti. The trio of publications appear January 25th in the open-access journal PLoS Neglected Tropical Diseases.

The recent outbreaks of cholera in Haiti, Pakistan, and Zimbabwe suggest that current global action plans against cholera are failing. "Although everyone agrees that the ultimate prevention and control of cholera will require provision of clean water and adequate sanitation to the world's population, the simple fact is that this will not be a reality for decades for the world's most impoverished, as well as for those affected by civil unrest and natural disasters," says Dr. Edward T. Ryan. "Less clear is the role that cholera vaccine could play once an outbreak has started. Classically, cholera would cause intensive and short outbreaks -- by the time the vaccine was distributed, it was thought that the window of possible benefit would have passed. However, Vibrio cholerae, the causative agent of cholera, has undergone a number of mutations in the last few years, and is now associated with longer outbreaks, and more severe clinical disease, leading to higher case totality rates and increased drug resistance." Because of all these features, researchers and public health officials have taken a new look at the potential role of cholera vaccine to help control outbreaks, combined with attempts to provide clean water and improve sanitation.

Reyburn and colleagues model the effect of cholera vaccine once an outbreak has occurred using data from a number of recent outbreaks. The researchers modeled 50% and 75% vaccine coverage, with completion of vaccination ranging from "rapid" (10 weeks after an outbreak was first reported), to a "maximum" of completion of vaccination 33 weeks after an outbreak is first reported. They found that even delayed responses could have benefit, and their model neither included herd effect modifiers, nor the effect that vaccination could have on subsequent disease burden after the initial outbreak has waned into an endemic situation.

Anh and colleagues describe a case-control study of the reactive use of the Vietnamese killed cholera vaccine during a significant outbreak in Hanoi. Administration of 1 or 2 doses of the vaccine was found to provide approximately 76% protective efficacy.

These reports will contribute to the discussion on the role that cholera vaccine could play in both short and long-term response plans, including the response in Haiti.


Story Source:

The above story is based on materials provided by Public Library of Science. Note: Materials may be edited for content and length.


Journal References:

  1. Dang Duc Anh, Anna Lena Lopez, Vu Dinh Thiem, Shannon L. Grahek, Tran Nhu Duong, Jin Kyung Park, Hye Jung Kwon, Michael Favorov, Nguyen Tran Hien, John D. Clemens. Use of Oral Cholera Vaccines in an Outbreak in Vietnam: A Case Control Study. PLoS Neglected Tropical Diseases, 2011; 5 (1): e1006 DOI: 10.1371/journal.pntd.0001006
  2. Rita Reyburn, Jacqueline L. Deen, Rebecca F. Grais, Sujit K. Bhattacharya, Dipika Sur, Anna L. Lopez, Mohamed S. Jiddawi, John D. Clemens, Lorenz von Seidlein. The Case for Reactive Mass Oral Cholera Vaccinations. PLoS Neglected Tropical Diseases, 2011; 5 (1): e952 DOI: 10.1371/journal.pntd.0000952

Cite This Page:

Public Library of Science. "Cholera vaccination beneficial, post-outbreak." ScienceDaily. ScienceDaily, 25 January 2011. <www.sciencedaily.com/releases/2011/01/110125172311.htm>.
Public Library of Science. (2011, January 25). Cholera vaccination beneficial, post-outbreak. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/01/110125172311.htm
Public Library of Science. "Cholera vaccination beneficial, post-outbreak." ScienceDaily. www.sciencedaily.com/releases/2011/01/110125172311.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins